Literature DB >> 22941443

Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial.

Christopher Horvath, Laura Andrews, Andreas Baumann, Lauren Black, Diann Blanset, Joy Cavagnaro, Kenneth L Hastings, David L Hutto, Timothy K MacLachlan, Mark Milton, Theresa Reynolds, Stan Roberts, Mark Rogge, Jennifer Sims, George Treacy, Garvin Warner, James D Green.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22941443     DOI： 10.1038/nri3192-c1

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


× No keyword cloud information.
  11 in total

Review 1.  Bacterial superantigens.

Authors:  T Proft; J D Fraser
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

2.  The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.

Authors:  Thomas Hünig
Journal:  Nat Rev Immunol       Date:  2012-04-10       Impact factor: 53.106

3.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

4.  CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28.

Authors:  M Tacke; G Hanke; T Hanke; T Hünig
Journal:  Eur J Immunol       Date:  1997-01       Impact factor: 5.532

5.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist.

Authors:  Chia-Huey Lin; Thomas Hünig
Journal:  Eur J Immunol       Date:  2003-03       Impact factor: 5.532

Review 6.  On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

Authors:  Philip J Lowe; Stacey Tannenbaum; Kai Wu; Peter Lloyd; Jennifer Sims
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-29       Impact factor: 4.080

Review 7.  On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.

Authors:  P J Lowe; Y Hijazi; O Luttringer; H Yin; R Sarangapani; D Howard
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

8.  Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice.

Authors:  Nicolas Legrand; Tom Cupedo; Anja U van Lent; Menno J Ebeli; Kees Weijer; Thomas Hanke; Hergen Spits
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

9.  Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.

Authors:  Fred Lühder; Yun Huang; Kevin M Dennehy; Christine Guntermann; Ingrid Müller; Erna Winkler; Thomas Kerkau; Shinji Ikemizu; Simon J Davis; Thomas Hanke; Thomas Hünig
Journal:  J Exp Med       Date:  2003-04-21       Impact factor: 14.307

10.  "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.

Authors:  Richard Stebbings; Lucy Findlay; Cherry Edwards; David Eastwood; Chris Bird; David North; Yogesh Mistry; Paula Dilger; Emily Liefooghe; Isabelle Cludts; Bernard Fox; Gill Tarrant; Jane Robinson; Tony Meager; Carl Dolman; Susan J Thorpe; Adrian Bristow; Meenu Wadhwa; Robin Thorpe; Stephen Poole
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422
View more
  16 in total

1.  The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.

Authors:  Marcel J H Kenter; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

Review 2.  Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative.

Authors:  Leonard A Levin; Joan W Miller; Donald J Zack; Martin Friedlander; Lois E H Smith
Journal:  Ophthalmology       Date:  2017-03-29       Impact factor: 12.079

Review 3.  Regulatory T cells in acute and chronic kidney diseases.

Authors:  Rahul Sharma; Gilbert R Kinsey
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-06

Review 4.  Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.

Authors:  Robert L Ferris; Binfeng Lu; Lawrence P Kane
Journal:  J Immunol       Date:  2014-08-15       Impact factor: 5.422

Review 5.  Humanized Mouse Models of Clinical Disease.

Authors:  Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

6.  Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model.

Authors:  Jamie L Brady; Leonard C Harrison; David J Goodman; Peter J Cowan; Wayne J Hawthorne; Philip J O'Connell; Robyn M Sutherland; Andrew M Lew
Journal:  Clin Transl Immunology       Date:  2014-12-19

7.  Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.

Authors:  Philip D Bardwell; Matthew M Staron; Junjian Liu; Qingfeng Tao; Susanne Scesney; Gail Bukofzer; Luis E Rodriguez; Chee-Ho Choi; Jennifer Wang; Qing Chang; Feng Dong; Cherrie Donawho; Jieyi Wang; Christine M Grinnell; Edit Tarcsa; Charles Hutchins; Tariq Ghayur; Jijie Gu
Journal:  Protein Cell       Date:  2017-06-05       Impact factor: 14.870

8.  TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model.

Authors:  Sabrina Weißmüller; Stefanie Kronhart; Dorothea Kreuz; Barbara Schnierle; Ulrich Kalinke; Jörg Kirberg; Kay-Martin Hanschmann; Zoe Waibler
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

9.  A non-conserved amino acid variant regulates differential signalling between human and mouse CD28.

Authors:  Nicla Porciello; Paola Grazioli; Antonio F Campese; Martina Kunkl; Silvana Caristi; Marta Mastrogiovanni; Michela Muscolini; Francesca Spadaro; Cédric Favre; Jacques A Nunès; Aldo Borroto; Balbino Alarcon; Isabella Screpanti; Loretta Tuosto
Journal:  Nat Commun       Date:  2018-03-14       Impact factor: 14.919

Review 10.  Humanized Mice as Unique Tools for Human-Specific Studies.

Authors:  Kylie Su Mei Yong; Zhisheng Her; Qingfeng Chen
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-02-07       Impact factor: 4.291
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.